Regular consumption of LIPIGO® promotes the reduction of body weight and improves the rebound effect of obese people undergo a comprehensive weight loss program

8Citations
Citations of this article
110Readers
Mendeley users who have this article in their library.

Abstract

Obesity is a global public health problem. Objective: To evaluate the effect of the regular consumption of the product Lipigo® on body weight and rebound effect on overweight/obese subjects undergoing a comprehensive weight loss program. Methods: A randomized, parallel, double-blind, placebo-controlled clinical trial was conducted with male and female subjects presenting a BMI 25–39.9 kg/m2. All subjects underwent a comprehensive weight loss program (WLP) for 12 weeks, which included an individualized hypocaloric diet, physical activity recommendations, nutritional education seminars, and three times a day consumption of the product Lipigo® or Placebo. After-WLP, subjects continued the treatment for 9 months to assess rebound effect. Body weight (BW), BMI, and body composition were measured at the beginning and the end of the WLP, and in the follow-up. Results: A total of 120 subjects (85% women) 49.0 ± 9.5 years old and with a BW of 81.57 ± 13.26 kg (BMI 31.19 ± 3.44 kg/m2) were randomized and 73 subjects finished the study. At the end of the WLP, there was a tendency toward reduced BW (p = 0.093), BMI (p = 0.063), and WC (p = 0.059) in the treated group. However, subjects with obesity type 1 (OB1) from the treated group significantly reduced body weight (−5.27 ± 2.75 vs. −3.08 ± 1.73 kg; p = 0.017) and BMI (−1.99 ± 1.08 vs. −1.09 ± 0.55 kg/m2; p = 0.01) compared with placebo. They also presented a minor rebound effect after 9 months with product consumption (−4.19 ± 3.61 vs. −1.44 ± 2.51 kg; p = 0.026), minor BMI (−1.61 ± 1.43 vs. −0.52 ± 0.96 kg/m2; p = 0.025) and tended to have less fat-mass (−3.44 ± 2.46 vs. −1.44 ± 3.29 kg; p = 0.080) compared with placebo. Conclusions: The regular consumption of the product Lipigo® promotes the reduction of body weight and reduces the rebound effect of obese people after 52 weeks (12 months), mainly in obesity type 1, who undergo a comprehensive weight loss program.

Cite

CITATION STYLE

APA

Valero-Pérez, M., Bermejo, L. M., López-Plaza, B., García, M. A., Palma-Milla, S., & Gómez-Candela, C. (2020). Regular consumption of LIPIGO® promotes the reduction of body weight and improves the rebound effect of obese people undergo a comprehensive weight loss program. Nutrients, 12(7), 1–14. https://doi.org/10.3390/nu12071960

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free